P

Precede Biosciences

Epigenomic liquid biopsy for cancer.

Scientist / Senior Scientist - Computational Biology

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeBoston, MA, USA$125k - $175k /yrHybrid

About the Job

Requirements

  • Experience using computational analyses of the epigenome to develop a compelling biological narrative.
  • Ability to present the biological narrative in a group setting.
  • Proficiency in either R with Bioconductor or Python.
  • Ability to take on new projects with minimal direction and adapt to feedback and evolving information.
  • Ability to work collaboratively on multidisciplinary teams.

Responsibilities

  • Blend biological insights with computational techniques to develop predictive models with immediate clinical applications.
  • Lead projects that bridge biological understanding of disease-relevant systems with computational analyses to drive diagnostic innovation.
  • Spearhead the analysis of novel epigenomic data and refine its clinical impact with a team of computational biologists.
  • Explore the biological underpinnings of numerous disease areas to produce biologically informed analyses that demonstrate significant endpoints.
  • Create novel classifiers with diagnostic relevance suitable for clinical use.
  • Collaborate with clinical, translational, computational, and product development stakeholders to make innovative diagnostics a reality.

About the Company

Precede Biosciences

Epigenomic liquid biopsy for cancer.

Precede Biosciences uses a blood test to read epigenomic signals in plasma. It analyzes circulating chromatin and the DNA methylome from a single milliliter of blood to determine the activation status of about 20,000 gene promoters and 1 million gene enhancers, providing a transcriptional biology view of disease. The platform supports drug development through Research Use Only partnerships with biopharmaceutical companies and academia, and aims to develop clinical blood-based tests that can replace invasive tissue biopsies for guiding precision medicines in cancers such as breast, lung, prostate, and colorectal. Unlike purely genomic tests, this approach focuses on epigenomic regulation to reveal disease biology, treatment response, and resistance. The company seeks to help identify therapeutic targets and mechanisms driving outcomes, with a goal of accelerating biomarker discovery and enabling non-invasive, dynamic insights into cancer biology.

Company size
51-200
Company stage
Series B
Total funding
$140.5M
Headquarters
Boston, MA
Founded
2021

Recently Posted Jobs

Explore more opportunities at Precede Biosciences

See more jobs